Provided by Tiger Fintech (Singapore) Pte. Ltd.

4D Molecular Therapeutics

4.24
-0.0700-1.62%
Post-market: 4.20-0.0400-0.94%16:47 EDT
Volume:196.32K
Turnover:828.08K
Market Cap:196.42M
PE:-1.34
High:4.34
Open:4.31
Low:4.13
Close:4.31
Loading ...

4D Molecular Therapeutics Inc. to Participate in RBC Capital Markets 2025 Global Healthcare Conference

Reuters
·
05 May

4D Molecular Therapeutics Inc expected to post a loss of 86 cents a share - Earnings Preview

Reuters
·
05 May

4D Molecular's Macular Edema Treatment Gets Regenerative Medicine Designation from FDA

MT Newswires Live
·
01 May

4Dmt Announces Rmat Designation Granted by FDA for 4D-150 for Dme

THOMSON REUTERS
·
01 May

4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME

GlobeNewswire
·
01 May

Discover Fractyl Health And 2 More Promising Penny Stocks

Simply Wall St.
·
22 Apr

4DMT Announces New Employment Inducement Grants

GlobeNewswire
·
12 Apr

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks
·
01 Apr

4DMT to Participate in Upcoming Investor Conferences

GlobeNewswire
·
27 Mar

4D Molecular Therapeutics Is Maintained at Buy by B of A Securities

Dow Jones
·
11 Mar

BRIEF-4DMT enrolls first patient in late-stage trial for its retinal eye disease therapy

Reuters
·
10 Mar

4Dmt Announces First Patients Enrolled in 4Front-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet Amd

THOMSON REUTERS
·
10 Mar

4D Molecular Therapeutics Inc - 4Front-2 Trial Expected to Initiate in Q3 2025

THOMSON REUTERS
·
10 Mar

Analysts Conflicted on These Healthcare Names: PTC Therapeutics (PTCT), 4D Molecular Therapeutics (FDMT) and Biohaven Ltd. (BHVN)

TIPRANKS
·
05 Mar

4D Molecular price target lowered to $35 from $39 at RBC Capital

TipRanks
·
04 Mar

Chardan Trims Price Target on 4D Molecular Therapeutics to $28 From $30, Keeps Buy Rating

MT Newswires Live
·
04 Mar

4D Molecular price target lowered to $28 from $30 at Chardan

TIPRANKS
·
04 Mar

4D Molecular Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
04 Mar

4D Molecular Therapeutics Price Target Maintained With a $36.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Mar

Analysts Offer Insights on Healthcare Companies: Akero Therapeutics (AKRO), Immunovant (IMVT) and 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
03 Mar